Arvinas (ARVN) Free Cash Flow Growth (3y) (2020 - 2026)
Arvinas (ARVN) Free Cash Flow Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 31.42% |
| 10 | Arvinas | 531.84 Mn | -83.06 Mn | - | 8.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.59% |
| Dec 31, 2025 | 25.80% |
| Sep 30, 2025 | 3.75% |
| Jun 30, 2025 | -7.85% |
| Mar 31, 2025 | -14.69% |
| Dec 31, 2024 | -32.72% |
| Sep 30, 2024 | -29.83% |
| Jun 30, 2024 | 44.76% |
| Mar 31, 2024 | -34.58% |
| Dec 31, 2023 | -33.99% |
| Sep 30, 2023 | -62.62% |
| Jun 30, 2023 | -56.66% |
| Mar 31, 2023 | -71.46% |
| Dec 31, 2022 | -81.39% |
| Sep 30, 2022 | -197.22% |
| Jun 30, 2022 | -79.74% |
| Mar 31, 2022 | -65.27% |
| Dec 31, 2021 | -52.37% |
| Sep 30, 2021 | 277.39% |
| Jun 30, 2021 | -57.86% |